Summary
Abbott Laboratories (ABT) has filed an 8-K report detailing a significant material definitive agreement. On February 23, 2026, the company entered into a pricing agreement to issue and sell $20 billion in aggregate principal amount of senior notes. These notes comprise various fixed-rate tranches with maturities ranging from 2029 to 2066, as well as a floating rate note due in 2029. The offering is being conducted under a shelf registration statement and will be made pursuant to a prospectus supplement filed on February 25, 2026. The primary use of the net proceeds from this substantial debt offering is to fund the consideration for the acquisition of Exact Sciences Corporation. Additionally, proceeds will be used to repay Exact Sciences' existing indebtedness, cover associated fees and expenses, and for general corporate purposes, which may include further debt repayment. The closing of this notes offering is anticipated on March 9, 2026, subject to standard closing conditions.
Key Highlights
- 1Abbott Laboratories entered into a pricing agreement to issue $20 billion in senior notes.
- 2The notes include a mix of floating rate and fixed rate senior notes with maturities spanning from 2029 to 2066.
- 3The offering is being conducted through Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc., and J.P. Morgan Securities LLC, among other underwriters.
- 4The primary purpose of the debt issuance is to finance the acquisition of Exact Sciences Corporation.
- 5Proceeds will also be used to repay Exact Sciences' indebtedness, cover transaction costs, and for general corporate purposes.
- 6The closing of the notes sale is expected on March 9, 2026, pending customary conditions.
- 7This 8-K filing is a notification of a material definitive agreement related to a significant financing and acquisition activity.